Company logo

BMEA - Biomea Fusion, Inc.

NASDAQ -> Healthcare -> Biotechnology
Redwood City, United States
Type: Equity

BMEA price evolution
BMEA
(in millions $) 30 Oct 2024 30 Jul 2024 1 May 2024 31 Jan 2024
Current assets
Cash
Short term investments
Net receivables
Inventory
Total current assets $93.6 $116.29 $147.57 $179.18
Long term investments
Property, plant & equipment $11.82 $12.76 $13.82 $14.87
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $110.42 $136.16 $168.49 $199.93
Current liabilities
Accounts payable $8.99 $5.83 $4.71 $6.85
Deferred revenue
Short long term debt
Total current liabilities $27.57 $25.16 $25.25 $22.86
Long term debt
Total noncurrent liabilities
Total debt
Total liabilities $34.45 $32.22 $33.18 $30.69
Shareholders' equity
Retained earnings -$357.95 -$325.16 -$287.89 -$248.82
Other shareholder equity
Total shareholder equity
(in millions $) 31 Jan 2024 31 Jan 2023 31 Jan 2022 31 Jan 2021
Current assets
Cash
Short term investments
Net receivables
Inventory
Total current assets $179.18 $117.82 $176.56 $62.22
Long term investments
Property, plant & equipment $14.87 $7.99 $5.69 $0.29
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $199.93 $129.31 $185.71 $62.53
Current liabilities
Accounts payable $6.85 $6.83 $1.33 $0.73
Deferred revenue
Short long term debt
Total current liabilities $22.86 $19.1 $4.64 $1.62
Long term debt
Total noncurrent liabilities
Total debt
Total liabilities $30.69 $20.77 $6.92 $1.62
Shareholders' equity
Retained earnings -$248.82 -$131.57 -$49.74 -$8.18
Other shareholder equity -$0 -$0.01
Total shareholder equity
(in millions $) 30 Oct 2024 30 Jul 2024 1 May 2024 31 Jan 2024
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $34.04 $38.9 $41.06 $37.33
Operating income
Income from continuing operations
EBIT
Income tax expense
Interest expense $1.25 $1.62 $2 $2.44
Net income
Net income -$32.79 -$37.28 -$39.06 -$34.88
Income (for common shares)
(in millions $) 31 Jan 2024 31 Jan 2023 31 Jan 2022 31 Jan 2021
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $126.14 $83.63 $5.33
Operating income
Income from continuing operations
EBIT
Income tax expense
Interest expense $8.88 $1.81
Net income
Net income -$117.25 -$81.83 -$5.32
Income (for common shares)
(in millions $) 30 Oct 2024 30 Jul 2024 1 May 2024 31 Jan 2024
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$0.28 -$0.09 -$0.04 -$2.22
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $1.25 $1.19 $0.12 $163.8
Effect of exchange rate
Change in cash and equivalents -$88.92 -$63.58 -$31.95 $64.99
(in millions $) 31 Jan 2024 31 Jan 2023 31 Jan 2022 31 Jan 2021
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$2.22 $27.34 -$33.35 -$0.05
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $163.8 $1.24 $153.19 $65.97
Effect of exchange rate
Change in cash and equivalents $64.99 -$33.84 $84.4 $61.46
Fundamentals
Market cap $153.29M
Enterprise value N/A
Shares outstanding 36.24M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income -$144.01M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -1.06
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS -$3.97
ROA -93.66%
ROE N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio 3.39
Quick ratio N/A